Enhanced reactivity of 5-HT1A receptors in the rat dorsal periaqueductal gray matter after chronic treatment with fluoxetine and sertraline: Evidence from the elevated T-maze

Neuropharmacology

Volumn 52, Issue 4, 2007, Pages 1188-1195

  Zanoveli, Janaina Menezes ^a   Nogueira, Regina Lúcia ^b   Zangrossi Jr , Hélio ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b ESTÁCIO DE SÁ UNIVERSITY   (Brazil)

Author keywords

Dorsal periaqueductal gray; Fluoxetine; Panic; Sensitization; Serotonin; Sertraline

Indexed keywords

FLUOXETINE; IMIPRAMINE; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AVOIDANCE BEHAVIOR; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DEFENSIVE BEHAVIOR; DRUG ACTIVITY; DRUG POTENTIATION; ESCAPE BEHAVIOR; MALE; MAZE TEST; MICROINJECTION; NEUROTRANSMISSION; NONHUMAN; PANIC; PERIAQUEDUCTAL GRAY MATTER; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; RAT;

8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; ANALYSIS OF VARIANCE; ANIMALS; BEHAVIOR, ANIMAL; DRUG INTERACTIONS; FLUOXETINE; MALE; MAZE LEARNING; PERIAQUEDUCTAL GRAY; RATS; RATS, WISTAR; REACTION TIME; RECEPTOR, SEROTONIN, 5-HT1A; SEROTONIN UPTAKE INHIBITORS; SERTRALINE;

EID: 33847280368     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2007.01.001     Document Type: Article

References (70)

1. Aghajanian G.K., Sprouse J.S., Sheldon P., and Rasmussen K. Electrophysiology of the central serotonin system: receptor subtypes and transducer mechanisms. Ann. N.Y. Acad. Sci. 600 (1990) 93-103 (discussion 103)
2. Amano K., Tanikawa T., Iseki H., Kawabatabe H., Notani M., Kawamura H., and Kitamura K. Single neuron analysis of the human midbrain tegmentum. Rostral mesencephalic reticulotomy for pain relief. Appl. Neurophysiol. 41 (1978) 66-78
3. Bakker A., van Balkom A.J., and van Dyck R. Selective serotonin reuptake inhibitors in the treatment of panic disorder and agoraphobia. Int. Clin. Psychopharmacol. Suppl. 2 (2000) S25-S30
4. Ballenger J.C. Pharmacological treatment of panic disorder. In: Den Boer J.A., and Stitse J.M.A. (Eds). Handbook of Depression and Anxiety (1994), Marcel Dekker, New York 275-289
5. Bandler R., Carrive P., and Depaulis A. Introduction: emerging principles of organization of the midbrain periaqueductal gray matter. In: Depaulis A., and Bandler R. (Eds). The Midbrain Periaqueductal Gray Matter: Functional, Anatomical and Neurochemical Organization (1991), Plenum Press, New York 1-8
6. Beck S.G., Birnstiel S., Choi K.C., and Pouliot W.A. Fluoxetine selectively alters 5-hydroxytryptamine1A and gamma-aminobutyric acidB receptor-mediated hyperpolarization in area CA1, but not area CA3, hippocampal pyramidal cells. J. Pharmacol. Exp. Ther. 281 1 (1997) 115-122
7. Beckett S.R.G., and Marsden C.A. The effect of central and systemic injection of the 5-HT1A receptor agonist 8-OH-DPAT and the 5-HT1A antagonist WAY 100635 on periaqueductal gray-induced defence behavior. J. Psychopharmacol. 11 1 (1997) 35-40
8. Bertoglio L.J., and Zangrossi Jr. H. Involvement of dorsolateral periaqueductal gray cholecystokinin-2 receptors in the regulation of a panic-related behavior in rats. Brain Res. 1059 1 (2005) 46-51
9. Bijak M., Tokarski K., Czyrak A., Mackowiak M., and Wedzony K. Imipramine increases the 5-HT1A receptor-mediated inhibition of hippocampal neurons without changing the 5-HT1A receptor binding. Eur. J. Pharmacol. 305 1-3 (1996) 79-85
10. Blier P., and de Montigny C. Current advances and trends in the treatment of depression. Trends Pharmacol. Sci. 15 7 (1994) 220-226
11. Bradwejn J., and Koszycki D. Cholecystokinin and panic disorder: past and future clinical research strategies. Scand. J. Clin. Lab. Invest. Suppl. 234 (2001) 19-27
12. de Bortoli V.C., Nogueira R.L., and Zangrossi Jr. H. Effects of fluoxetine and buspirone on the panicolytic-like response induced by the activation of 5-HT1A and 5-HT2A receptors in the rat dorsal periaqueductal gray. Psychopharmacology 183 4 (2006) 422-428
13. Connor K.M., and Davidson J.R.T. Generalized anxiety disorder: neurobiological and pharmacotherapeutic perspectives. Biol. Psychiatry 44 (1998) 1286-1294
14. Cryan J.F., and Leonard B.E. 5-HT1A and beyond: the role of serotonin and its receptors in depression and the antidepressant response. Hum. Psychopharmacol. 15 2 (2000) 113-135
15. Den Boer J.A., and Westenberg H.G. Serotonin function in panic disorder: a double blind placebo controlled study with fluvoxamine and ritanserin. Psychopharmacology 102 1 (1990) 85-94
16. Den Boer J.A., and Slaap B.R. Review of current treatment in panic disorder. Int. Clin. Psychopharmacol. 13 Suppl. 4 (1998) 25-30
17. Donoghue J., and Hylan T.R. Antidepressant use in clinical practice: efficacy v. effectiveness. Br. J. Psychiatry Suppl. 42 (2001) S9-S17
18. Elena Castro M., Diaz A., Del Olmo E., and Pazos A. Chronic fluoxetine induces opposite changes in G protein coupling at pre and postsynaptic 5-HT1A receptors in rat brain. Neuropharmacology 44 (2003) 93-101
19. Feighner J.P., and Boyer W.F. Serotonin-1A anxiolytics: an overview. Psychopathology 22 Suppl. 1 (1989) 21-26
20. Graeff F.G. Brain defense systems and anxiety. In: Roth M., Burrows G.D., and Noyes R. (Eds). Handbook of Anxiety. The Neurobiology of Anxiety vol. 3 (1990), Elsevier Science Publishers, Amsterdam 307-354
21. Graeff F.G. New concepts in anxiety. In: Briley M., and File S.E. (Eds). Neurotransmitters in the Dorsal PAG and Animal Models of Panic Anxiety (1991), The MacMillan Press Ltd., London 288-312
22. Graeff F.G., Viana M.B., and Tomaz C. The elevated T maze, a new experimental model of anxiety and memory: effect of diazepam. Braz. J. Med. Biol. Res. 26 1 (1993) 67-70
23. Graeff F.G., Netto C.F., and Zangrossi Jr. H. The elevated T-maze as an experimental model of anxiety. Neurosci. Biobehav. Rev. 23 2 (1998) 237-246
24. Graeff F.G. On serotonin and experimental anxiety. Psychopharmacology 163 3-4 (2002) 467-476
25. Graeff F.G., and Zangrossi Jr. H. Textbook of biological psychiatry. In: D'Haenen H., den Boer J.A., Westenberg H., and Willner P. (Eds). Animal Models of Anxiety Disorders (2002), Wiley and Sons, London 879-893
26. Graeff F.G. Serotonin, the periaqueductal gray and panic. Neurosci. Biobehav. Rev. 28 3 (2004) 239-259
27. Griebel G., Blanchard D.C., Agnes R.S., and Blanchard R.J. Differential modulation of antipredator defensive behavior in Swiss-Webster mice following acute or chronic administration of imipramine and fluoxetine. Psychopharmacology (Berl.) 120 1 (1995) 57-66
28. Hensler J.G., Kovachich G.B., and Frazer A. A quantitative autoradiographic study of serotonin1A receptor regulation. Effect of 5,7-dihydroxytryptamine and antidepressant treatments. Neuropsychopharmacology 4 2 (1991) 131-144
29. Hensler J.G. Differential regulation of 5-HT1A receptor-G protein interactions in brain following chronic antidepressant administration. Neuropsychopharmacology 26 5 (2002) 565-573
30. Hensler J.G. Regulation of 5-HT1A receptor function in brain following agonist or antidepressant administration. Life Sci. 72 15 (2003) 1665-1682
31. Hjorth S., Bengtsson H.J., Kullberg A., Carlzon D., Peilot H., and Auerbach S.B. Serotonin autoreceptor function and antidepressant drug action. J. Psychopharmacol. 14 2 (2000) 177-185
32. 2 receptor-mediated inhibition of panic-like behavior in the rat dorsal periaqueductal gray. Pharmacol. Biochem. Behav. 72 4 (2002) 761-766
33. Jenck F., Broekkamp C.L., and Van Delft A.M. The effect of antidepressants on aversive periaqueductal gray stimulation in rats. Eur. J. Pharmacol. 177 3 (1990) 201-204
34. Jenck F., Moreau J.L., and Martin J.R. Dorsal periaqueductal gray-induced aversion as a simulation of panic anxiety: elements of face and predictive validity. Psychiatry Res. 57 (1995) 181-191
35. Kamijima K., and Aoki M. Effectiveness of paroxetine in the treatment of obsessive-compulsive disorders. Expert Rev. Neurother. 6 7 (2006) 945-956
36. Kia H.K., Brisorgueil M.J., Hamon M., Calas A., and Verge D. Ultrastructural localization of 5-hydroxytryptamine 1A receptors in the rat brain. J. Neurosci. Res. 46 (1996) 697-708
37. Klein D.F., and Flink M. Psychiatric reaction patterns to imipramine. J. Psychiatry 119 (1962) 432-438
38. Klimek V., Zak-Knapik J., and Mackowiak M. Effects of repeated treatment with fluoxetine and citalopram, 5-HT uptake inhibitors, on 5-HT1A and 5-HT2 receptors in the rat brain. J. Psychiatry Neurosci. 19 1 (1994) 63-67
39. Kocsis J.H. Pharmacotherapy for chronic depression. J. Clin. Psychol. 59 8 (2003) 885-892
40. Kurt M., Arik A.C., and Celik S. The effects of sertraline and fluoxetine on anxiety in the elevated plus-maze test in mice. J. Basic Clin. Physiol. Pharmacol. 11 2 (2000) 173-180
41. Lepola U., Arato M., Zhu Y., and Austin C. Sertraline versus imipramine treatment of comorbid panic disorder and major depressive disorder. J. Clin. Psychiatry 64 6 (2003) 654-662
42. Liebowitz M.R., Fyer A.J., Gorman J.M., Campeas R.B., Sandberg D.P., Hollander E., Papp L.A., and Klein D.F. Tricyclic therapy on the DSM-III anxiety disorders: a review with implications for further research. J. Psychiatr. Res. 22 (1988) 7-31
43. Lovick T.A. Panic disorder - a malfunction of multiple transmitter control systems within the midbrain periaqueductal gray matter. Neuroscientist 6 (2000) 48-59
44. Maj J., Bijak M., Dziedzicka-Wasylewska M., Rogoz R., Rogoz Z., Skuza G., and Tokarski T. The effects of paroxetine given repeatedly on the 5-HT receptor subpopulations in the rat brain. Psychopharmacology 127 1 (1996) 73-82
45. 1A-receptor-mediated inhibition of panic-like behaviours. Psychopharmacology 131 4 (1997) 321-328
46. Nashold Jr. B.S., Wilson W.P., and Slaughter D.G. Sensations evoked by stimulation in the midbrain of man. J. Neurosurg. 30 1 (1969) 14-24
47. Nierenberg A.A., Farabaugh A.H., Alpert J.E., Gordon J., Worthington J.J., Rosenbaum J.F., and Fava M. Timing of onset of antidepressant response with fluoxetine treatment. Am. J. Psychiatry 157 (2000) 1423-1428
48. Nogueira R.L., and Graeff F.G. Role of 5-HT receptor subtypes in the modulation of dorsal periaqueductal gray aversion. Pharmacol. Biochem. Behav. 52 1 (1995) 1-6
49. Olds M.E., and Olds J. Approach-escape interactions in rat brain. Am. J. Physiol. 203 (1962) 803-810
50. Owens M.J., Knight D.L., and Nemeroff C.B. Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol. Psychiatry 50 5 (2001) 345-350
51. de Paula Soares V., and Zangrossi Jr. H. Involvement of 5-HT1A and 5-HT2 receptors of the dorsal periaqueductal gray in the regulation of the defensive behaviors generated by the elevated T-maze. Brain Res. Bull. 64 2 (2004) 181-188
52. Paxinos G., and Watson C. The Rat Brain in Stereotaxic Coordinates. third ed. (1997), Academic, San Diego
53. Pineyro G., and Blier P. Autoregulation of serotonin neurons: role in antidepressant drug action. Pharmacol. Rev. 51 3 (1999) 533-591
54. Poltronieri S., Zangrossi Jr. H., and Viana M.B. Antipanic-like effect of serotonin reuptake inhibitors in the elevated T-maze. Behav. Brain Res. 147 1-2 (2003) 185-192
55. Salchner P., and Singewald N. 5-HT receptor subtypes involved in the anxiogenic-like action and associated Fos response of acute fluoxetine treatment in rats. Psychopharmacology (Berl.) 185 3 (2006) 282-288
56. Sanchez C., and Hyttel J. Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. Cell. Mol. Neurobiol. 19 4 (1999) 467-489
57. Schenberg L.C., Bittencourt A.S., Sudre E.C., and Vargas L.C. Modeling panic attacks. Neurosci. Biobehav. Rev. 25 7-8 (2001) 647-659
58. 35S]GTPγS binding in rat brain neurons. Neuropharmacology 42 (2002) 1031-1038
59. Sheehan D.V., Raj A.B., Harnett-Sheehan K., Soto S., and Knapp E. The relative efficacy of high-dose buspirone and alprazolam in the treatment of panic disorder: a double-blind placebo-controlled study. Acta Psychiatr. Scand. 88 1 (1993) 1-11
60. Sheehan D.V. Current concepts in the treatment of panic disorder. J. Clin. Psychiatry 60 Suppl. 18 (1999) 16-21
61. Stahl S.M. Mechanism of action of serotonin selective reuptake inhibitors. Serotonin receptors and pathways mediate therapeutic effects and side effects. J. Affect. Disord. 51 3 (1998) 215-235
62. Sullivan P.W., Valuck R., Saseen J., and MacFall H.M. A comparison of the direct costs and cost effectiveness of serotonin reuptake inhibitors and associated adverse drug reactions. CNS Drugs 18 13 (2004) 911-932
63. Teixeira R.C., Zangrossi Jr. H., and Graeff F.G. Behavioral effects of acute and chronic imipramine in the elevated T-maze model of anxiety. Pharmacol. Biochem. Behav. 65 4 (2000) 571-576
64. Treit D., Menard J., and Royan C. Anxiogenic stimuli in the elevated plus-maze. Pharmacol. Biochem. Behav. 44 2 (1993) 463-469
65. Verge D., Daval G., Marcinkiewicz M., Patey A., el Mestikawy S., Gozlan H., and Hamon M. Quantitative autoradiography of multiple 5-HT1 receptor subtypes in the brain of control or 5,7-dihydroxytryptamine-treated rats. J. Neurosci. 6 12 (1986) 3474-3482
66. Viana M.B., Tomaz C., and Graeff F.G. The elevated T-maze: a new animal model of anxiety and memory. Pharmacol. Biochem. Behav. 49 3 (1994) 549-554
67. Zangrossi Jr. H., and Graeff F.G. Behavioral validation of the elevated T-maze, a new animal model of anxiety. Brain Res. Bull. 44 1 (1997) 1-5
68. Zanoveli J.M., Nogueira R.L., and Zangrossi Jr. H. Serotonin in the dorsal periaqueductal gray modulates inhibitory avoidance and one-way escape behaviors in the elevated T-maze. Eur. J. Pharmacol. 473 2-3 (2003) 153-161
69. Zanoveli J.M., Netto C.F., Guimaraes F.S., and Zangrossi Jr. H. Systemic and intra-dorsal periaqueductal gray injections of cholecystokinin sulfated octapeptide (CCK-8s) induce a panic-like response in rats submitted to the elevated T-maze. Peptides 25 11 (2004) 1935-1941
70. Zanoveli J.M., Nogueira R.L., and Zangrossi Jr. H. Chronic imipramine treatment sensitizes 5-HT1A and 5-HT 2 A receptors in the dorsal periaqueductal gray matter: evidence from the elevated T-maze test of anxiety. Behav. Pharmacol. 16 7 (2005) 543-552